Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders
Crescita Therapeutics Inc. (CRRTF) held its 2021 Annual General and Special Meeting in Laval, Québec, where shareholders voted on key matters. All nominated directors were elected with significant support: Daniel N. Chicoine (86.9%), David A. Copeland (96.5%), Anthony E. Dobranowski (94.8%), John C. London (96.5%), and Thomas Schlader (94.7%). Ernst & Young was reappointed as external auditors with 89.1% approval. Furthermore, Crescita's Share Incentive Plan was approved with 84.7% support. The company remains focused on delivering innovative dermatology solutions.
- High shareholder support for elected directors, ranging from 86.9% to 96.5%.
- Reappointment of Ernst & Young as external auditors indicates confidence in financial oversight.
- Approval of the Share Incentive Plan with 84.7% support fosters employee retention and motivation.
- Some directors received significant votes withheld, indicating potential shareholder discontent.
Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its 2021 Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Québec. The detailed results of the votes received by proxy are as follows:
Election of Directors
Director Nominees |
|
|
||||
|
|
|
|
|||
Daniel N. Chicoine |
2,549,254 |
383,576 |
86.9 |
% |
13.1 |
% |
David A. Copeland |
2,829,180 |
103,650 |
96.5 |
% |
3.5 |
% |
Anthony E. Dobranowski |
2,779,033 |
153,797 |
94.8 |
% |
5.2 |
% |
John C. London |
2,830,264 |
102,566 |
96.5 |
% |
3.5 |
% |
Thomas Schlader |
2,777,856 |
154,974 |
94.7 |
% |
5.3 |
% |
Appointment of External Auditors
Outcome |
|
|
||||
|
|
|
|
|||
Ernst & Young LLP reappointed |
3,240,957 |
394,460 |
89.1 |
% |
10.9 |
% |
Approval of the Continuation of Crescita’s Share Incentive Plan
Outcome |
|
|
||||
|
|
|
|
|||
Share Incentive Plan approved |
2,485,187 |
447,643 |
84.7 |
% |
15.3 |
% |
About Crescita Therapeutics Inc.
Crescita (TSX: CTX and OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research and development (“R&D”) and manufacturing capabilities. The Company offers a portfolio of high-quality, science-based non-prescription skincare products and early to commercial stage prescription products. In addition, we own multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into or through the skin.
Our non-prescription portfolio includes a wide variety of premium quality dermocosmetic products which include facial creams, cleansers, exfoliants, masks, serums and suncare, that each serve a different and personalized consumer need. The portfolio is designed to address preventive care to combating the first signs of aging, as well as all primary aesthetic skin concerns. Our dermocosmetic products address two sub-sets of the skincare market: aesthetics and medical aesthetics. In Canada, our national sales force calls on aesthetic practitioners and medical aesthetic clinics and medispas using a business to business to consumer model. LDR products can also be purchased through our online platform. Our skincare brands are also sold in certain Asian markets, such as Malaysia, South Korea and China through international distributors and through various e-commerce platforms.
Crescita’s portfolio also includes Pliaglis, our lead prescription product, that utilizes our proprietary phase-changing topical cream Peel technology. Pliaglis is a topical local anesthetic cream that provides safe and effective local dermal analgesia on intact skin prior to superficial dermatological procedures. The product is currently approved in over 25 different countries, is sold by commercial partners in the U.S., Italy, Spain and Brazil, and was most recently licensed to partners in Austria, Mexico and China. We also market Pliaglis in the Canadian physician-dispensed skincare market through our own sales force.
Our expertise in topical product formulation and development can be leveraged in combination with our patented transdermal delivery technologies to develop and manufacture creams, liquids, gels, ointments and serums under our contract development and manufacturing organization infrastructure. We run our operations from our head office located in the heart of the Biotech City in Laval, Québec, where we also manufacture the majority of our non-prescription skincare products in our 50,000 square-foot facility.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210512005509/en/
FAQ
What were the voting results for Crescita Therapeutics' directors in 2021?
Who were reappointed as external auditors for Crescita Therapeutics?
What changes were made to Crescita Therapeutics' Share Incentive Plan in 2021?
